Streetbeat News

Regulatory

ANVS

Annovis Bio, Inc. (NYSE:ANVS) has received a positive safety review from the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer's Disease patients. The DSMB recommended that Annovis Bio continue the trial as originally designed. The trial of buntanetap was initiated in late March 2023 and to date, 281 patients have been recruited out of the planned 320. In phase 2 trials, buntanetap was observed to improve cognition and speed of thinking.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 8:46 pm

PARA

PARAA

Vice President Kamala Harris stated that the U.S. has no intention to send ground troops to Israel or Gaza amid the conflict with Hamas. Instead, the U.S. is offering diplomatic support, advice, and equipment to Israel. Harris also emphasized the importance of providing safety and security for the Palestinians and separating them from Hamas. The interview was broadcast on CBS, owned by Paramount Global (NASDAQ:PARA)(NASDAQ:PARAA).

Portfolio Pulse from Chris Katje

October 30, 2023 | 8:41 pm

AENT

Alliance Entertainment Holding Corporation (NASDAQ:AENT) has regained compliance with Nasdaq Listing Rule 5250(c)(1) by filing its annual report on Form 10-K for the fiscal year ended June 30, 2023. The company received a written notice from the Nasdaq Stock Market LLC confirming its compliance.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 8:39 pm

TLT

The US Treasury Department's quarterly refunding announcement is expected to reveal its strategy to increase sales of long-term debt. This comes as long-term bonds have been falling for weeks, despite the Federal Reserve hinting at a possible cessation of interest rate hikes. The iShares 20+ Year Treasury Bond ETF (NASDAQ:TLT) has fallen 18% year to date, following a 33% drop in 2022. Market participants are watching to see if the pace of expansion in longer-term debt sales will continue.

Portfolio Pulse from Piero Cingari

October 30, 2023 | 8:13 pm

SRPT

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced topline results from EMBARK, a Phase 3 clinical study of ELEVIDYS in patients with Duchenne muscular dystrophy. The results showed statistically significant results on all key pre-specified secondary endpoints, demonstrating evidence of a clinically meaningful treatment benefit. The US FDA has indicated openness to reviewing the data for label expansion. Sarepta plans to host an investor call on October 30.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 8:06 pm

PNXP

Pineapple Express Cannabis Company (OTCPK: PNXP) is offering up to 5 million shares of its common stock at $1 per share, aiming to raise $5 million. The shares are available to accredited investors in compliance with Regulation D, Rule 506(c) under the Securities Act of 1933. The funds raised will be used for the company's strategic plan of launching 10 fully licensed retail cannabis dispensaries in the metro Los Angeles area and financing general corporate operations.

Portfolio Pulse from Joana Scopel

October 30, 2023 | 8:04 pm

SRPT

Shares of Sarepta Therapeutics have been halted due to pending news.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 8:01 pm

EIS

SPY

USO

John Kirby, the White House's NSC Coordinator for Strategic Communications, has stated that they do not believe a ceasefire is the right answer now. This could potentially impact the geopolitical landscape and related assets.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 7:56 pm

BNTX

MRNA

PFE

SPY

The CDC anticipates that the upcoming fall and winter respiratory disease season will likely result in a similar number of hospitalizations as the previous season.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2023 | 7:23 pm

GOOG

GOOGL

MSFT

NVDA

President Joe Biden has issued an executive order establishing new standards for AI safety and security. The order requires leading AI companies to share safety results and other relevant information with the U.S. government. It also mandates the National Institute of Standards to develop new tools and tests to ensure AI systems' safety and security. The order will impact major U.S. tech companies such as OpenAI, Microsoft Corp, Alphabet Inc, and NVIDIA Corp.

Portfolio Pulse from Aaron Bry

October 30, 2023 | 6:52 pm